Statement re EU Grant Awarded

Proteome Sciences PLC
13 February 2004






                                                             13th February, 2004

                 PROTEOME SCIENCES EU 6th FRAMEWORK GRANT AWARD
                       FOR DRUG TREATMENT FOR DEPRESSION

Proteome Sciences plc ('Proteome Sciences') is pleased to announce that it has
been successful in a European Commission 6th Framework Grant Application for a 3
year programme, GENDEP, to explore patient response to drugs for mood disorders
and depression. This will be conducted as a large scale multi-centre human
pharmacogenomic study with a total budget of €7.5 million and will focus on the
prediction of therapeutic response to anti-depressants and adverse effects with
a specific award to Proteome Sciences of €438,000. The programme will provide a
platform to identify new targets for drug discovery and for the early diagnosis
of disease and to predict responders and non-responders to anti-depressant
treatments.

This follows shortly after the announcement on 9th February, 2004 where Proteome
Sciences was awarded a DTI-Link grant of £419,000 in Alzheimer's with the
Institute of Psychiatry, King's College, London to improve the early detection
of the disease and for the discovery of new targets for therapy. Diagnosis of
Alzheimer's depends on early clinical assessment and there are currently no
diagnostic assays available.

Christopher Pearce, Chief Executive of Proteome Sciences commented :

'The award of the EU 6th Framework grant to explore patient response to drugs
for mood disorders and depression takes Proteome Sciences into a new field
within neurosciences. This is entirely complementary to the research which is
already underway and provides access to further leading centres of expertise
across Europe.

Both of the grants awarded recognise the requirement to address the fast growing
prevalence of neurological disorders in a society where life expectancy has
increased so considerably. Our ProteoSHOP(R) toolkit provides a unique
combination of technologies to address differential protein expression in
disease and where the grant funding will accelerate its application and utility
in the most debilitating disease areas of Alzheimer's and depression.'

                                    - ENDS -


For further information please contact:

Proteome Sciences plc
Christopher Pearce, Chief Executive Tel: [phone]
Email: [e-mail]
Website: www.proteomics.com
Public Relations for Proteome Sciences
IKON Associates
Adrian Shaw Tel: [phone]
Mobile: [phone]
Email: [e-mail]

Notes to Editors:

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications. It has to date developed sensitive
blood assays for stroke, vCJD, BSE and solid organ transplant rejection.

The main focus of its research currently addresses neurological,
neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions.
Commercialisation of these programmes will be effected through strategic
alliances and licensing agreements.

Proteome Sciences is headquartered in Cobham, Surrey in the UK and has research
facilities in London and Frankfurt. The Company has been listed on the
Alternative Investment Market since 1995.




                      This information is provided by RNS
            The company news service from the London Stock Exchange